| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| rp173355-500μg |
500μg |
期货  |
| |
| rp173355-1mg |
1mg |
期货 |
|
| 产品名称 | abatacept, CD80 融合蛋白;CD86 融合蛋白 |
|---|---|
| 别名 | 阿巴西普 |
| 英文别名 | BMS-188667 | CTLA4-IgG4m | Orencia,RG-1046 | RG-2077 |
| 规格或纯度 | Moligand™ |
| 作用类型 | 抑制剂 |
| 作用机制 | CD80 融合蛋白;CD86 融合蛋白 |
| CAS编号和信息 | rp173355 |
|---|
| 1. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. (1991) CTLA-4 is a second receptor for the B cell activation antigen B7.. J Exp Med, 174 (3): (561-9). [PMID:1714933] |
| 2. Ludvigsson J. (2016) Therapies to Preserve β-Cell Function in Type 1 Diabetes.. Drugs, 76 (2): (169-85). [PMID:26645223] |
| 3. Davis IC, Randell J, Davis SN. (2015) Immunotherapies currently in development for the treatment of type 1 diabetes.. Expert Opin Investig Drugs, 24 (10): (1331-41). [PMID:26364507] |
| 4. Douthwaite J, Moisan J, Privezentzev C, Soskic B, Sabbah S, Cohen S, Collinson A, England E, Huntington C, Kemp B et al.. (2017) A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding.. J Immunol, 198 (1): (528-537). [PMID:27881707] |
首页
400-620-6333
